- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Donna Hansel Discusses Challenges When Treating Advanced Bladder Cancer
Funding is the biggest challenge scientists and clinical investigators face when trying to find successful therapies to treat advanced bladder cancer, explained Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine.
Funding is the biggest challenge scientists and clinical investigators face when trying to find successful therapies to treat advanced bladder cancer, explained Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine.
Transcript
What has been the challenge with finding successful therapies to treat advanced bladder cancer?
I think one of the biggest challenges, historically, has always been funding for scientists and clinical investigators to better understand the disease. There has been phenomenal advocacy through groups like the bladder cancer advocacy network to help improve the funding paradigm through their own efforts and through lobbying of the [National Cancer Institute]. It’s certainly nowhere near enough to entice people to come and spend a lot of basic science effort in this field. I think it’s changing. And I think we are going to make great progress.
I think a second aspect, as far as identifying unique therapies and bladder cancer, really has to do with building a link between what we’re understanding more and more of related to genomic alterations and being able to tie that into mechanistically what’s happening at the protein and cell level. Ultimately, as we design drug targets, we’re really looking at the protein and while the genomic signature is so important in helping us understand upstream what’s happening, I think we can’t lose focus on understanding the cell biology that accompanies that.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
